



1

Today's meeting is jointly provided by:

- Wisconsin Alzheimer's Institute
- Interprofessional Continuing Education Partnership
- Wisconsin Geriatric Education Center
- Wisconsin Alzheimer's Disease Research Center



Wisconsin Alzheimer's Institute
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICAL AND PUBLIC HEALTH



Interprofessional
Continuing Education Partnership
UNIVERSITY OF WISCONSIN



WISCONSIN
GERIATRIC
EDUCATION
CENTER



Wisconsin Alzheimer's
Disease Research Center
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICAL AND PUBLIC HEALTH

2

TEXT VERIFICATION CODE

BUPMOY
to
(608) 260-7097

TO VERIFY YOUR ATTENDANCE
FOR THIS ACTIVITY

You **MUST** be registered for this course to use the code.

3

Faculty/Planner Disclosures

- Faculty/Planners with relevant financial relationships, which have been mitigated, are listed below. No other faculty/planners for this activity have relevant financial relationships with ineligible companies to disclose.

Name	Role	Financial Relationship Disclosures	Discussion of Unlabeled/ Unapproved Uses of Drugs/Devices in Presentation?
Cynthia Carlsson	Speaker/Author	Cognition Therapeutics (Grant), Axon Neuroscience (Grant), Alkermes Pharmaceuticals Inc. (Grant), Ionis Pharmaceuticals (Grant), Eli Lilly and Company (Grant), Eisai (Grant), Eli Lilly and Company (Grant), Exact Sciences (Employment ended 10/25)	No
Adam Flyte	Planner		No
Maria Mora Pinzon	Planner	Neolix (Contractor)	No
Henrik Zetterberg	Speaker/Author	Roche Diagnostics GmbH (Contractor), Labcorp (Contractor), Denali Therapeutics (Contractor), Siemens (Contractor), Biogen (Contractor), Eisai (Contractor), Eli Lilly and Company (Contractor), Fujirebio Europe (Contractor), Novo Nordisk (Contractor)	No



4

Dementia Diagnostic Clinic Network

Inception, 1998 with 5 clinics
35 affiliate clinics
20 counties
19 different healthcare systems
Geriatrics – 12
Neurology – 12
Psychiatry – 6
Family Practice – 3
Internal Medicine – 2



5

Trends in AD/DRD Care and Management

Resources for clinicians: <https://www.alz.org/alz-pro>

ALZHEIMER'S ASSOCIATION | ALZPro®

Content Hubs

Discover featured content across three main content hubs and resources – then learning and go to the relevant content and resources – then learning and go to the relevant content and resources



6

Assessing Cognitive Concerns in Primary Care

Newly developed, a **customizable 2-appointment assessment workflow** for primary care providers who have older adult patients presenting with concerns about cognitive changes.

Completing a basic cognitive work-up when a patient reports cognitive concerns enables the primary care provider to:

1. Identify and treat potentially reversible causes of cognitive symptoms (e.g., sleep apnea, depression, hypothyroidism).
2. Evaluate medication adherence and chronic disease management.
3. Promote brain health through evidence-based lifestyle interventions.
4. Address patient and family questions and concerns.
5. Provide aging well guidance, including education, safety planning, community resources, and advance care planning.

No-cost assistance available to primary care providers and healthcare systems includes:

- Consultation
 - Workflow start-up assistance
 - Virtual peer consultation with an experienced clinician
 - Guidance on standard dementia care practices
 - Local community-based and educational resources
- Patient materials (e.g., Aging Well and Maximizing Brain Health)
- Training and networking opportunities

Assessing Cognitive Changes in Primary Care workflow contributors:

Cynthia Carlsson, MD, MS	Jody Krainer, MSW, LCSW
Nathaniel Chiu, MD	Tom Loepple, MD
Lindsay Clark, PhD	Robert P. Smith, MD
Joan Hamblin, MD	Mark Van Etten, MD
Derek L. Jones, MD	Victoria Williams, PhD

Wisconsin Alzheimer's Institute
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

For more information, contact Jody Krainer at jkrainer@wisc.edu

7

3-Part Webinar Series

Gain practical strategies to assess and support older adults with cognitive concerns using Wisconsin Alzheimer's Institute's **primary care 2-appointment assessment workflow**.

Webinar 1 | December 1, 2026 | Noon-100 PM
Conducting a Basic Cognitive Assessment

- Why assess cognition in primary care?
- Overview of the streamlined 2-appointment workflow
- Demonstration of recommended screening tools

Webinar 2 | December 8, 2026 | Noon-100 PM
Interpreting Results & Engaging Patients and Families

- Clinical decision-making after assessment
- Communicating findings effectively
- Connecting patients and families to resources

Webinar 3 | December 15, 2026 | Noon-100 PM
Coding, Billing & Workflow Implementation

- Billing opportunities for cognitive assessment
- Implementing the 2-appointment workflow
- Available practice support and resources

Webinar Series Planning Committee

Wendy Betley	Daniel McCulley, MD
Cynthia Carlsson, MD, MS	John Trimberger, MD
Jody Krainer, MSW, LCSW, MBA	Trisha Witham

Registration





Wisconsin Alzheimer's Institute
Models of Clinical Care

Assessing Cognitive Concerns in
PRIMARY CARE

Webinar Presenters

Cynthia Carlsson, MD, MS
Nathaniel Chiu, MD
Jody Krainer, MSW, LCSW, MBA
Richard London, MD
Trisha Witham

8

Trends in AD/DRD Care and Management

Therapeutic updates:

- FDA approved subcutaneous lecanemab for treatment initiation for MCI/dementia due to AD
- Safety profiles of anti-amyloid therapies are being shown in newer publications from real world data from patients in clinics
 - Paczynski M et al. JAMA Neurology 2025;82(7):655-665. (Wash Univ)
 - Brosch JR et al. Alzheimer's Dement. 2026 Jul 8;12(3):e70291. (Indiana Univ)

Wisconsin Alzheimer's Institute
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

9

Cochrane Review 2026

Caused Confusion Regarding Anti-Amyloid Therapies

Lecanemab and donanemab

- reduce amyloid
- slow cognitive decline, BUT do not stop or reverse cognitive decline

Wisconsin Alzheimer's Institute
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH
van Dyck, et al. N Engl J Med 2023; 388(9-10):969-979; Simons et al. JAMA 2023; 329(6):552-557

10

Cochrane Review 2026

Caused Confusion Regarding Anti-Amyloid Therapies

Wisconsin Alzheimer's Institute
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH
<https://www.cochranelibrary.com/cds/doi/10.1002/14658858.CD062987/full>

11

New Trials Starting at UW-Madison

<https://adrc.wisc.edu/open-studies>

New studies evaluating:

- Donanemab and mivelsiran in Down syndrome (APPlauDS, ALADDIN)
- Anti-tau therapies in combination with donanemab (ATP)
- Newer brainshuttle anti-amyloid trontinemab (PreventTRON)
- Cholesterol medication obicetrapib
- Curcumin extract (TML-6)
- Probiotics (Gut-PRO)

Legend: Phase II (red), Phase III (yellow), Phase IV (green)

12

4

New Studies Starting at UW-Madison

Help shape the future of dementia care!

The Driving Connections Lab

looking for people to be on a

Dementia Research Advisory Board

Who can join the advisory board?

Physicians, healthcare professionals, social workers, care with experience working with patients with dementia and having conversations about driving safety. We want to hear from you!

What would you need to do?

You would join virtual meetings to talk about your thoughts on dementia care and how clinicians can improve support for patients who need to stop driving.

When and where will the meetings be held?

The meetings will take place on-line via Zoom. We plan on holding six 60- to 75-minute meetings over six to eight months.

Will you get paid?

Yes, if you participate, you will receive \$75 for each meeting you attend and a \$50 honorarium for attending all six meetings.

How to join the advisory board

For more information contact us: drivingconnections@wisc.edu or 608-263-1000



Kellia (K.J.) Hansmann,
MD, MPH, PhD

13

Save-the-Dates



May 14, 2027

- Core Skills Training
- Spring Meeting

September 16-17, 2027

- Fall Meeting
- 25th Annual Conference



Wisconsin Alzheimer's Institute
UNIVERSITY OF WISCONSIN
SCHOOL OF MEDICINE AND PUBLIC HEALTH

14

5